"Genentech is Disneyland for scientists."
I joined Genentech in November 2015 as scientist in the Department of Preclinical Translational Pharmacokinetics (PTPK).
Our department contributes to antibody based drug development from very early stages such as target validation, molecule design and lead selection to lead optimization and first-in-human dose strategies. I represent PTPK in cancer immunotherapy (CIT) programs and support the pipeline for better therapeutic options for the patients in need.
Our group focuses on specific PK issues, such as distribution, stability, exposure, related to CIT programs. We help designing and selecting the right molecule taking into consideration target properties as well as downstream pharmacology. Our group works very closely with CIT group and other research group to deliver state-of-art therapies into clinic safely and efficiently.